Table 4. Multivarate analysis for overall survival and progression-free survival.
|
Overall survival |
Progression-free survival |
|||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
|
Stage | ||||||
| LD | Reference | Reference | ||||
| ED |
1.546 |
1.072–2.230 |
0.020 |
1.700 |
1.193–2.422 |
0.003 |
|
LDH | ||||||
| Normal | Reference | Reference | ||||
| Elevated |
1.507 |
1.078–2.107 |
0.016 |
1.658 |
1.199–2.294 |
0.002 |
|
NLR at diagnosis | ||||||
| <4 | Reference | Reference | ||||
| ⩾4 |
1.465 |
1.012–2.119 |
0.043 |
1.474 |
1.033–2.105 |
0.032 |
|
PLR at diagnosis | ||||||
| <160 | Reference | Reference | ||||
| ⩾160 | 0.896 | 0.628–1.280 | 0.547 | 0.961 | 0.685–1.347 | 0.816 |
Abbreviations: CI=confidence interval; ED=extensive disease; HR=hazard ratio; LDH=lactate dehydrogenase; NLR=neutrophil-lymphocyte ratio; PLR=platelet-lymphocyte ratio.